Island Bolsters US Biodefence Readiness Ahead of Trials
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Island Pharmaceuticals Ltd has announced an expansion of its engagement in the US biodefence sector, particularly ahead of its planned studies for Galidesivir under the FDA Animal Rule. Island is also increasing its involvement with the Medical Countermeasures Coalition, focusing on research and procurement initiatives related to biodefence. The company is on track to commence dose optimisation studies for Galidesivir, aimed at treating Marburg Virus Disease, in the upcoming quarter.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Island Pharmaceuticals Ltd on 6ix
Earlier from Island Pharmaceuticals
- Antiviral pipeline expansion through strategic collaboration
- US Government collaboration for Galidesivir development
- Trading Halt
- Appendix 4D & Half-Year Financial Statements
- Response to ASX Query Letter
Later from Island Pharmaceuticals
- Island Adds Biodefence Leader as Filovirus Risks Escalate
- Island Advances Galidesivir GMP Manufacturing for Biodefence
- Island Secures USAMRIID Support for Galidesivir Study
- Investor presentation
- Investor Presentation - Asia Dengue Summit
Follow Island Pharmaceuticals into a list and get an email when it puts out news.
Follow Island Pharmaceuticals